Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Sarker, Debashis
Borek, Weronika E.
Pedicona, Federico
Zen, Yoh
Christopher, Josie A.
Karampera, Christina
Campbell, Amy
Khorsandi, Shirin Elizabeth
Dowe, Thomas
Habarwaa, Marwo
Britton, David James
Heaton, Nigel
Cutillas, Pedro Rodriguez
Williamson, Andrew
Dokal, Arran David
机构：
[1] Kings Coll Hosp London, Inst Liver Studies, London, England
[2] Kinomica Ltd, Macclesfield, Cheshire, England
[3] Kings Coll Hosp London, London, England
[4] Queen Mary Univ London, Barts Canc Inst, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2631
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA
    Cappuyns, Sarah
    Pique-Gili, Marta
    Esteban-Fabro, Roger
    Philips, Gino
    Pinyol, Roser
    Vandecaveye, Vincent
    Abril-Fornaguera, Jordi
    Haber, Philipp
    Verslype, Chris
    Van Cutsem, Eric
    Lambrechts, Diether
    Villanueva, Augusto
    Dekervel, Jeroen
    Llovet, Josep M.
    HEPATOLOGY, 2023, 78 : S1871 - S1872
  • [2] Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC)
    Salani, F.
    Guerri, V.
    Cesario, S.
    Sammuri, P.
    Genovesi, V.
    Pratesi, F.
    Massa, V.
    Catanese, S.
    Vivaldi, C.
    Fornaro, L.
    Crea, F.
    Migliorini, P.
    Galimberti, S.
    Masi, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S32 - S32
  • [3] Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
    Chon, Young Eun
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kang, Beodeul
    Ha, Yeonjung
    Kim, Do Young
    Hwang, Seong Gyu
    Chon, Hong Jae
    Kim, Beom Kyung
    CANCER MEDICINE, 2023, 12 (03): : 2731 - 2738
  • [4] Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
    Yano, Shigeki
    Kawaoka, Tomokazu
    Johira, Yusuke
    Miura, Ryoichi
    Kosaka, Masanari
    Shirane, Yuki
    Murakami, Serami
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Kosaka, Yumi
    Yamaoka, Kenji
    Kodama, Kenichiro
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ohno, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Imamura, Michio
    Mori, Keiichi
    Arihiro, Kouji
    Kuroda, Shintaro
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Aikata, Hiroshi
    MEDICINE, 2021, 100 (42) : E27576
  • [5] Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
    Persano, M.
    Rimini, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Presa, J.
    Masi, G.
    Bergamo, F.
    Iavarone, M. A.
    Cabibbo, G.
    Foschi, F. G.
    Piscaglia, F.
    Cascinu, S.
    Scartozzi, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1535
  • [6] Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma
    Manfredi, G. F.
    Fulgenzi, C. A. M.
    D'Alessio, A.
    Celsa, C.
    Stefanini, B.
    Cheon, J.
    Ang, C.
    Marron, T. U.
    Saeed, A.
    Wietharn, B.
    Pressiani, T.
    Pinter, M.
    Scheiner, B.
    Huang, Yi-Hsiang
    Phen, S.
    Naqash, A. Rafeh
    Piscaglia, F.
    Lin, R. Po-Ting
    Lin, C. -yen
    Dalbeni, A.
    Vivaldi, C.
    Masi, G.
    Thimme, R.
    Vogel, A.
    Schonlein, M.
    von Felden, J.
    Schulze, K.
    Wege, H.
    Galle, P. R.
    Kudo, M.
    Rimassa, L.
    Singal, A.
    Sharma, R.
    Cortellini, A.
    Chon, H. Jae
    Burlone, M.
    Pirisi, M.
    Pinato, D. J.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S8 - S9
  • [7] Extracellular Vesicles May Predict Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma
    Egerer, Mara
    Schuch, Kathrin
    Schoeler, David
    Artusa, Fabian
    Puengel, Tobias
    Holtman, Theresa Maria
    Loosen, Sven H.
    Demir, Muenevver
    Wree, Alexander
    Luedde, Tom
    Tacke, Frank
    Roderburg, Christoph
    Mohr, Raphael
    CANCERS, 2024, 16 (21)
  • [8] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
  • [9] Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma
    Choi, Se Jin
    Chung, Sung Won
    Choi, Jonggi
    Kim, Kang Mo
    Kim, Hyung-Don
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Lee, Seung Soo
    Choi, Won-Mook
    Choi, Sang Hyun
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 1219 - 1230
  • [10] Result of atezolizumab plus bevacizumab for advanced or metastatic hepatocellular carcinoma in Vietnamese patients
    Hoang, H. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S88 - S88
12345